FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Solo a fini di ricerca. Disposizione completa →

Libreria Peptidica

PNC-27

p53-MDM2 Peptide

Fat Loss & Body Composition

PNC-27 is a synthetic anti-cancer peptide consisting of a sequence derived from the p53 tumor suppressor protein (residues 12-26) linked to a membrane-penetrating (HDM-2 binding) domain that selectively targets and destroys cancer cells expressing HDM-2 (Human Double Minute 2) on their surface membrane. Unlike most chemotherapeutic agents, PNC-27 induces rapid membranolysis (membrane destruction) and necrosis specifically in cancer cells while leaving normal cells unaffected due to the absence of surface HDM-2 in healthy tissue. It remains in the preclinical research stage with no human clinical trials completed.

Meccanismo d'azione

Chimeric peptide combining an HDM-2 binding domain with a cell-penetrating sequence. Selectively targets cells with membrane-associated HDM-2 (overexpressed in many cancer cells), creating pores that trigger necrosis. Spares normal cells lacking surface HDM-2.

Protocolli di ricerca

Solo per scopi di ricerca. Non è consiglio medico.

Research is primarily in vitro and animal models. No established human dosing protocols. Cancer research studies used 50-200mcg/ml in cell culture. In vivo studies used local injection into tumors.

Note di ricerca

Clinical Research Status

PNC-27 has been extensively studied in preclinical cell culture and animal models by the research group of Dr. Ehsan Ehsanipour and collaborators, with publications spanning multiple cancer cell types over the past two decades. No human clinical trials have been registered or completed, and the compound remains firmly in the laboratory research phase. The selective cytotoxicity demonstrated in vitro has generated significant interest, but translation to clinical use faces challenges including peptide stability, delivery, pharmacokinetics, and manufacturing at therapeutic scale.

Key Published Findings

Studies demonstrate that PNC-27 induces rapid necrosis (within hours) in multiple cancer cell lines including breast (MDA-MB-231, MCF-7), pancreatic (MIA PaCa-2), and leukemia cells while showing no toxicity to normal cells at equivalent concentrations. The mechanism involves binding to HDM-2 protein aberrantly expressed on the surface of cancer cells (but not normal cells), leading to membrane pore formation, loss of membrane integrity, and necrotic cell death. Importantly, the cytotoxic mechanism is independent of p53 status in the cancer cell, meaning it can kill p53-mutant cancers that are resistant to conventional therapies.

Safety Profile

In vitro studies consistently show that PNC-27 has no cytotoxic effect on normal human fibroblasts, lymphocytes, or other non-transformed cells at concentrations that kill cancer cells. Animal studies using xenograft tumor models have not reported significant systemic toxicity at effective anti-tumor doses. However, comprehensive toxicology studies, pharmacokinetic profiling, and maximum tolerated dose determinations have not been published, and the peptide's behavior in complex human physiology remains unknown.

Comparison to Related Compounds

PNC-27 is unique among anti-cancer peptides in targeting a specific oncogenic surface marker (HDM-2) rather than general differences in membrane charge or composition that other antimicrobial/anticancer peptides exploit. Unlike conventional chemotherapy which kills rapidly dividing cells indiscriminately, PNC-27's selectivity is based on a molecular marker of malignant transformation. Compared to antibody-drug conjugates (ADCs) and immune checkpoint inhibitors, PNC-27 represents a simpler molecular approach but faces similar challenges in tumor penetration and peptide drug delivery.

Community Observations

PNC-27 generates significant interest in alternative cancer research communities due to its selectivity and novel mechanism, though access outside of research settings is essentially impossible. The peptide is occasionally discussed in online forums alongside other experimental cancer compounds, with patients and advocates expressing frustration at the slow pace of clinical translation. Legitimate researchers caution that impressive in vitro results do not guarantee clinical efficacy, as many promising cancer compounds fail in the transition from cell culture to human patients.

Semplifichro

~Unknown

Riconcimimento

Sterile PBS or bacteriostatic water

Conservazione

Lyofilizzato

Store at -20C. Extremely sensitive to degradation.

Riconcimato

Prepare fresh. Use within 24 hours.

Stato legale USA

Research chemical (not FDA-approved)

Anche noto come

p53-MDM2 Peptide

Domande frequenti

Che cos'è PNC-27?

PNC-27 is a synthetic anti-cancer peptide consisting of a sequence derived from the p53 tumor suppressor protein (residues 12-26) linked to a membrane-penetrating (HDM-2 binding) domain that selectively targets and destroys cancer cells expressing HDM-2 (Human Double Minute 2) on their surface membrane. Unlike most chemotherapeutic agents, PNC-27 induces rapid membranolysis (membrane destruction) and necrosis specifically in cancer cells while leaving normal cells unaffected due to the absence of surface HDM-2 in healthy tissue. It remains in the preclinical research stage with no human clinical trials completed.

Come agisce PNC-27?

Chimeric peptide combining an HDM-2 binding domain with a cell-penetrating sequence. Selectively targets cells with membrane-associated HDM-2 (overexpressed in many cancer cells), creating pores that trigger necrosis. Spares normal cells lacking surface HDM-2.

Qual è lo stato normativo di PNC-27 negli Stati Uniti?

Research chemical (not FDA-approved)

Qual è l'emivita di PNC-27?

~Unknown

Con quali altri nomi è noto PNC-27?

p53-MDM2 Peptide

Peptide Contacts fornisce riassunti basati su ricerche a fini informativi soltanto. Non ospitiamo, distribuiamo o endossiamo le comunicazioni dei fornitori. Tutti i certificati di analisi, certificati GMP e comunicazioni del fornitore devono essere richiesti e verificati direttamente dall'acquirente. Niente su questa piattaforma costituisce consigli legali, medici o professionali. I utenti sono responsabili unicamente della verifica delle credenziali dei fornitori e dell'assicurazione del rispetto di tutte le leggi locali, regionali e federali applicabili prima di acquistare qualsiasi chimica di ricerca. L'uso di questa piattaforma costituisce l'accettazione piena della responsabilità personale.

Leggi l'intera dichiarazione di responsabilità